{"filing":{"accession_number":"0001171843-26-005912","cik":"0001505065","ticker":"BRSYF","company_name":"Brainsway Ltd.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"f6k_090626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505065/000117184326005912/f6k_090626.htm"},"events":[{"id":31788,"run_id":29187,"accession_number":"0001171843-26-005912","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces publication of peer-reviewed pilot study results showing 83.3% response rate and 50% remission rate for BrainsWay's Deep TMS technology in patients with depression and early-stage Alzheimer's disease, with measurable neurophysiological changes. While the study is preliminary and not FDA-cleared for Alzheimer's indication, the positive clinical findings and peer-reviewed publication represent a material operational/scientific milestone that would affect investor assessment of the company's product pipeline and clinical evidence base. This is not an earnings release (no financial results), but rather a clinical/product development milestone that is material to the company's strategic positioning.","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34774,"accession_number":"0001171843-26-005912","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces publication of peer-reviewed pilot study results showing 83.3% response rate and 50% remission rate for BrainsWay's Deep TMS technology in patients with depression and early-stage Alzheimer's disease, with measurable neurophysiological changes. While the study is preliminary and not FDA-cleared for Alzheimer's indication, the positive clinical findings and peer-reviewed publication represent a material operational/scientific milestone that would affect investor assessment of the company's product pipeline and clinical evidence base. This is not an earnings release (no financial results), but rather a clinical/product development milestone that is material to the company's strategic positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:31:42.021593+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34774,"accession_number":"0001171843-26-005912","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces publication of peer-reviewed pilot study results showing 83.3% response rate and 50% remission rate for BrainsWay's Deep TMS technology in patients with depression and early-stage Alzheimer's disease, with measurable neurophysiological changes. While the study is preliminary and not FDA-cleared for Alzheimer's indication, the positive clinical findings and peer-reviewed publication represent a material operational/scientific milestone that would affect investor assessment of the company's product pipeline and clinical evidence base. This is not an earnings release (no financial results), but rather a clinical/product development milestone that is material to the company's strategic positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:31:42.021593+00:00","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-09-08"}]}